Treatment of central precocious puberty by GnRH analogs: Long-term outcome in men

Asian Journal of Andrology

Volumn 10, Issue 4, 2008, Pages 525-534

  Bertelloni, Silvano ^a   Mul, Dick ^b  

^a UNIVERSITY OF PISA   (Italy)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Adolescent; Adult height; Central precocious puberty; Gonadotropin releasing hormone analog safety; Gonadotropin releasing hormone analog treatment; Long term outcome; Male

Indexed keywords

BUSERELIN; DESLORELIN; GONADORELIN DERIVATIVE; GONADOTROPIN; GOSERELIN; HISTRELIN; LEUPRORELIN; TRIPTORELIN;

BODY HEIGHT; BOY; CLINICAL TRIAL; DATA ANALYSIS; DRUG WITHDRAWAL; FOLLOW UP; GONADOTROPIN RELEASE; HUMAN; MALE; OUTCOME ASSESSMENT; PRECOCIOUS PUBERTY; PUBLICATION; REVIEW;

ADOLESCENT; ADULT; BODY HEIGHT; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PUBERTY, PRECOCIOUS; SEX CHARACTERISTICS; TREATMENT OUTCOME;

EID: 45749091389     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00409.x     Document Type: Review

References (64)

1. Partsch CJ, Heger S, Sippell WG. Management and outcome of central precocious puberty. Clin Endocrinol (Oxf) 2002; 56: 129-48.
2. Grumbach MM, Styne DM. Puberty: Ontogeny, neuroendocrinology, physiology, and disorders. In: Wilson JD, Foster DW, Kronenberg HM, Larsen PR, editors, Williams Textbook of Endocrinolgy, 9th edn, Philadelphia: W.B. Saunders, 1998, p 1509-625.
3. Wilson AC, Meethal SV, Bowen RL, Atwood CS. Leuprolide acetate: A drug of diverse clinical applications. Expert Opin Investig Drugs 2007; 16: 1851-63.
4. Lee PA, Houk CP. Gonadotropin-releasing hormone analog therapy for central precocious puberty and other childhood disorders affecting growth and puberty. Treat Endocrinol 2006; 5: 287-96.
5. Thamdrup E. Precocious Sexual Development, a Clinical Study of 100 Children. Kopenhagen: Munksgaard, 1961, 104-5.
6. Bridges NA, Christopher JA, Hindmarsh PC, Brook CG. Sexual precocity: sex incidence and aetiology. Arch Dis Child 1994; 70: 116-8.
7. Cisternino M, Arrigo T, Pasquino AM, Tinelli C, Antoniazzi F, Beduschi L, et al. Etiology and age incidence of precocious puberty in girls: A multicentric study. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 695-701.
8. De Sanctis V, Corrias A, Rizzo V, Bertelloni S, Urso L, Galluzzi F, et al. Etiology of central precocious puberty in males: The results of the Italian Study Group for Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 687-93.
9. Chemaitilly W, Trivin C, Adan L, Gall V, Sainte-Rose C, Brauner R. Central precocious puberty: Clinical and laboratory features. Clin Endocrinol (Oxf) 2001; 54: 289-94.
10. Klein KO, Barnes KM, Jones JV, Feuillan PP, Cutler GB Jr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: The National Institutes of Health experience. J Clin Endocrinol Metab 2001; 86: 4711-6.
11. Sigurjonsdottir TJ, Hayles AB. Precocious puberty. A report of 96 cases. Am J Dis Child 1968; 115: 309-21.
12. Bovier-Lapierre M, Sempe M, David M. Aspects tiologiques, cliniques et biologiques des pubertes precoces d'origine centrale. Pediatrie 1972; 27: 587-609.
13. Paul D, Conte FA, Grumbach MM, Kaplan, SL. Long-term effect of gonadotropin releasing hormone agonist therapy on final and near-final height in 26 children with true precocious puberty treated at a median age of less than 5 years. J Clin Endocrinol Metab 1995; 80: 546-51.
14. Tanner JM, Whitehouse ER. Clinical longitudianl standards for height, weight, height velocity, weight velocity and stages of puberty. Arch Dis Child 1976; 51; 170-9.
15. Carel JC, Lahlou N, Roger M, Chaussain JL. Precocious puberty and statural growth. Hum Reprod Update 2004; 10: 135-47.
16. Mul D, Bertelloni S, Carel JC, Saggese G, Chaussain JL, Oostdijk W. Effect of gonadotropin-releasing hormone agonist treatment in boys with central precocious puberty. Horm Res 2002; 58: 1-7.
17. Cesario SK, Hughes LA. Precocious puberty: A comprehensive review of literature. J Obstet Gynecol Neonatal Nurs 2007; 36: 263-74.
18. Stewart L, Steinbok P, Daaboul J. Role of surgical resection in the treatment of hypothalamic hamartomas causing precocious puberty. Report of six cases. J Neurosurgur 1998; 88: 340-5.
19. Feuillan PP, Jones JV, Barnes KM, Oerter-Klein K, Cutler GB. Boys with precocious puberty due to hypothalamic hamartoma: Reproductive axis after discontinuation of gonadotropin-releasing hormone analog therapy. J Clin Endocrinol Metab 2000; 85: 4036-8.
20. Feuillan PP, Jones JV, Barnes K, Oerter-Klein K, Cutler GB. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty. J Clin Endocrinol Metab 1999; 84: 44-9.
21. Lahlou N, Carel JC, Chaussain JL, Roger M. Pharmacokinetics and pharmacodynamics of GnRH agonists: Clinical implications in pediatrics. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 723-37.
22. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarrevan de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: The Dutch experience. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 765-72.
23. Carel JC, Roger M, Ispas S, Tondu F, Lahlou N, Blumberg J, et al. Final height after long-term treatment with Triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment. J Clin Endocrinol Metab 1999; 84: 1973-8.
24. Galluzzi F, Salti R, Bindi G, Pasquini E, La Cauza C. Adult height comparison between boys and girls with precocious puberty after long-term gonadotrophin-releasing hormone analogue therapy. Acta Paediatrica 1998; 87: 521-7.
25. Heger S, Partsch CJ, Sippell WG. Long-term outcome after depot gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density, and reproductive function. J Clin Endocrinol Metab 1999; 84: 4583-90.
26. Adan L, Chemaitilly W, Trivin C, Brauner R. Factors predicting adult height in girls with central precocious puberty: Implications for treatment. Clin Endocrinol 2002; 56: 297-302.
27. Bertelloni S, Baroncelli GI, Ferdeghini M, Menchini-Fabris F, Saggese G. Final height, gonadal function and bone mineral density of adolescent males with central precocious puberty after therapy with gonadotropin-releasing hormone analogues. Eur J Pediatr 2000; 159: 369-74.
28. Pasquino AM, Pucarelli I, Accardo F, Demiraj V, Segni M, Di Nardo R. Long-term observation of 87 girls with idiopathic central precocious puberty treated with GnRH analogues: Impact on adult height, body mass index, bone mineral content and reproductive function. J Clin Endocrinol Metab 2008; 93: 190-5.
29. Rizzo V, De Sanctis V, Corrias A, Fortini M, Galluzzi F, Bertelloni S, et al. Factors influencing final/near-final height in 12 boys with central precocious puberty treated with gonadotrophin-releasing hormone agonists. Italian Study Group of Physiopathology of Puberty. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 781-6.
30. Carel JC, Lahlou N, Guazzarotti L, Joubert-Collin M, Roger M, Colle M, et al. Treatment of central precocious puberty with depot leuprorelin. French Leuprorelin Trial Group. Eur J Endocrinol 1995; 132: 699-704.
31. Clemons RD, Kappy MS, Stuart TE, Perelman AH, Hoekstra FT. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty. Am J Dis Child 1993; 147: 653-7.
32. Neely EK, Hintz RL, Parker B, Bachrach LK, Cohen P, et al. Two-year results of treatment with depot leuprolide acetate for central precocious puberty. J Pediatr 1992; 121: 634-40.
33. Tanaka T, Hibi I, Kato K, Saito S, Shimizu N, Suwa S, Nakajima H. A dose finding study of a super long-acting luteinizing hormone-releasing hormone analog (leuprolide acetate depot, TAP-144-SR) in the treatment of central precocious puberty. The TAP-144-SR CPP Study Group. Endocrinology 1991; 38: 369-76.
34. Tanaka T, Niimi H, Matsuo N, Fujieda K, Tachibana K, Ohyama K, et al. Results of long-term follow-up after treatment of central precocious puberty with leuprorelin acetate: Evaluation of effectiveness of treatment and recovery of gonadal function. The TAP-144-SR Japanese Study Group on Central Precocious Puberty. J Clin Endocrinol Metab 2005; 90: 1371-6.
35. Cook JS, Doty KL, Conn PM, Hansen JR. Assessment of depot leuprolide acetate dose-adequacy for central precocious puberty. J Clin Endocrinol Metab 1992; 74: 1206-9.
36. Paterson WF, McNeill E, Reid S, Hollman AS, Donaldson MD. Efficacy of Zoladex LA (goserelin) in the treatment of girls with central precocious or early puberty. Arch Dis Child 1998; 79: 323-7.
37. de Brito VN, Latronico AC, Arnhold IJ, Lo LS, Domenice S, Albano MC, Fragoso MC, et al. Treatment of gonadotropin dependent precocious puberty due to hypothalamic hamartoma with gonadotropin releasing hormone agonist depot. Arch Dis Child 1999; 80: 231-4.
38. Carel JC, Lahlou N, Jaramillo O, Montauban V, Teinturier C, Colle M, et al. Treatment of central precocious puberty by subcutaneous injections of leuprorelin 3-month depot (11.25 mg). J Clin Endocrinol Metab 2002; 87: 4111-16.
39. Trueman JA, Tillmann V, Cusick CF, Foster P, Patel L, Hall CM, et al. Suppression of puberty with long-acting goserelin (Zoladex-LA): Effect on gonadotrophin response to GnRH in the first treatment cycle. Clin Endocrinol (Oxf) 2002; 57: 223-30.
40. Paterson WF, McNeill E, Young D, Donaldson MD. Auxological outcome and time to menarche following long-acting goserelin therapy in girls with central precocious or early puberty. Clin Endocrinol (Oxf) 2004; 61: 626-34.
41. Martínez-Aguayo A, Hernández MI, Beas F, Iñiguez G, Avila A, Sovino H, et al. Treatment of central precocious puberty with triptorelin 11.25 mg depot formulation. J Pediatr Endocrinol Metab 2006; 19: 963-70.
42. Bertelloni S, Cassio A, Arrigo T, Wasniewska M, Galluzzi F, Einaudi S, et al. Central precocious puberty: Short-term comparative data of treatment with montly or long-acting three months depot triptorelin. J Pediatr Endocrinol Metab 2007; 20 (Suppl 2): 297-305.
43. Eugster EA, Clarke W, Kletter GB, Lee PA, Neely EK, Reiter EO, et al. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: A multicenter trial. J Clin Endocrinol Metab 2007; 92: 1697-704.
44. Lazar L, Pertzelan A, Weintrob N, Philipp M, Kauli R. Sexual precocity in boys: Accelerated versus slowly progressive puberty gonadotropin-suppressive therapy and final height. J Clin Endocrinol Metab 2001; 86: 4127-32.
45. Mul D, Oostdijk W, Otten BJ, Rouwe C, Jansen M, Delemarrevan de Waal HA, et al. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: The Dutch experience. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 765-72.
46. Bajpai A, Sharma J, Kabra M, Gupta AK, Menon PS. Long-acting GnRH analogue triptorelin therapy in central isosexual precocious puberty. Indian Pediatr 2002; 39: 633-9.
47. Kauli R, Galatzer A, Kornreich L, Lazar L, Pertzelan A, Laron Z. Final height of girls with central precocious puberty, untreated versus treated with cyproterone acetate or GnRH analogue. A comparative study with re-evaluation of predictions by the Bayley-Pinneau method. Horm Res 1997; 47: 54-61.
48. Virdis R, Street ME, Bandello MA, Tripodi C, Donadio A, Villani AR, et al. Growth and pubertal disorders in Neurofibromatosis type 1. J Pediatr Endocrinol Metab 2003; 16 (Suppl 2): 285-8.
49. Palmert T, Malin HV, Boepple PA. Unsustained or slowly progressive puberty in young girls: Initial presentation and long-term follow-up of 20 untreated patients. J Clin Endocrinol Metab 1999; 84: 415-23.
50. Leger J, Reynaud R, Czernichow P. Do all girls with apparent idiopathic precocious puberty require gonadotropin-releasing hormone agonist treatment? J Pediatr 2000; 137: 819-25.
51. Bertelloni S, Baroncelli GI, Sorrentino MC, Perri G, Saggese G. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females. Eur J Pediatr 1998; 157: 363-7.
52. Arrigo T, Cisternino M, Galluzzi F, Bertelloni S, Pasquino AM, Antoniazzi F, et al. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999; 141: 140-4.
53. Manasco PK, Pescovitz OH, Feuillan PP, Hench KD, Barnes KM, Jones J, et al. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty. J Clin Endocrinol Metab 1988; 67: 3668-72.
54. Serter S, Gümüş B, UnlüM, Tunçyürek O, Tarhan S, Ayyildiz V, Pabuscu Y. Prevalence of testicular microlithiasis in an asymptomatic population. Scand J Urol Nephrol 2006; 40: 212-4.
55. Jaganathan K, Ahmed S, Henderson A, Rané A. Current management strategies for testicular microlithiasis. Nat Clin Pract Urol 2007; 4: 492-7.
56. Ringdahl E, Claybrook K, Teague JL, Northrup M. Testicular microlithiasis and its relation to testicular cancer on ultrasound findings of symptomatic men. J Urol 2004; 172: 1904-6.
57. Chiumello G, Brambilla P, Guarneri MP, Russo G, Manzoni P, Sgaramella P. Precocious puberty and body composition: Effects of GnRH analog treatment. J Pediatr Endocrinol Metab 2000; 13 (Suppl 1): 791-4.
58. Traggiai C, Perucchin PP, Zerbini K, Gastaldi R, De Biasio P, Lorini R. Outcome after depot gonadotrophin-releasing hormone agonist treatment for central precocious puberty: Effects on body mass index and final height. Eur J Endocrinol 2005; 153: 463-4.
59. Palmert MR, Mansfield MJ, Crowley WF Jr, Crigler JF Jr, Crawford JD, Boepple PA. Is obesity an outcome of gonadotropin-releasing hormone agonist administration? Analysis of growth and body composition in 110 patients with central precocious puberty. J Clin Endocrinol Metab 1999; 84: 4480-8.
60. Arrigo T, De Luca F, Antoniazzi F, Galluzzi F, Segni M, Rosano M, et al. Reduction of baseline body mass index under gonadotropin-suppressive therapy in girls with idiopathic precocious puberty. Eur J Endocrinol 2004; 150: 533-7.
61. Chiocca E, Dati E, Bertelloni S. Bone mass and body composition in adolescent girls treated by gonadotrophin releasing hormone analogue for central precocious puberty. 9th International Symposium on GnRH: "The hypothalamic-pituitary-gonadal axis in cancer and reproduction", Berlin, 10-12 February 2008.
62. van der Sluis IM, Boot AM, Krenning EP, Drop SL, de Muinck Keizer-Schrama SM. Longitudinal follow-up of bone density and body composition in children with precocious or early puberty before, during and after cessation of GnRH agonist therapy. J Clin Endocrinol Metab 2002; 87: 506-12.
63. Antoniazzi F, Bertoldo F, Zamboni G, Valentini R, Sirpresi S, Cavallo L, et al. Bone mineral metabolism in girls with precocious puberty during gonadotrophin-releasing hormone agonist treatment. Eur J Endocrinol 1995; 133: 412-7.
64. Tung YC, Lee JS, Tsai WY, Hsiao PH. The effects of gonadotropin releasing hormone analogue therapy on girls with gonadotropin-dependent precocious puberty. J Formos Med Assoc 2007; 106: 826-31.